このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Precision BioSciences 過去の業績

過去基準チェック /06

Precision BioSciencesは15.4%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで15.5%毎年増加している。売上は成長しており、年平均15.8%の割合である。

主要情報

15.4%

収益成長率

43.0%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	15.8%
株主資本利益率	-53.7%
ネット・マージン	-34.7%
前回の決算情報	31 Mar 2024

Recent updates

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Aug 06

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Jun 23

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Mar 14

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Dec 08

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Sep 02

Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Apr 19

Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)

Mar 21

Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely

Dec 31

Precision BioSciences: Uniquely Positioned

Oct 07

Is Precision BioSciences (NASDAQ:DTIL) A Risky Investment?

Sep 24

Precision BioSciences: The Right Profile To Progress

Aug 27

収支内訳

Precision BioSciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:DTIL 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 24	58	-20	39	53
31 Dec 23	49	-43	41	51
30 Sep 23	52	-57	43	59
30 Jun 23	47	-40	43	34
31 Mar 23	31	-59	44	35
31 Dec 22	25	-73	43	44
30 Sep 22	21	-76	47	55
30 Jun 22	38	-93	44	92
31 Mar 22	102	-40	44	106
31 Dec 21	116	-31	43	112
30 Sep 21	118	-32	42	109
30 Jun 21	101	-47	42	106
31 Mar 21	34	-101	40	95
31 Dec 20	24	-109	39	95
30 Sep 20	22	-106	38	92
30 Jun 20	19	-101	37	87
31 Mar 20	24	-88	35	84
31 Dec 19	22	-93	30	79
30 Sep 19	21	-87	25	77
30 Jun 19	18	-76	21	67
31 Mar 19	15	-69	17	56
31 Dec 18	11	-46	15	44
30 Sep 18	7	-38	12	35
31 Dec 17	6	-21	9	19
31 Dec 16	7	-8	7	9

質の高い収益: DTILは現在利益が出ていません。

利益率の向上: DTILは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: DTILは利益を出していないが、過去 5 年間で年間15.4%の割合で損失を削減してきた。

成長の加速: DTILの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: DTILは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: DTILは現在利益が出ていないため、自己資本利益率 ( -53.73% ) はマイナスです。

Precision BioSciences 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Precision BioSciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Precision BioSciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Precision BioSciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q2, 2023 Results on Aug 04, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress

Precision BioSciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Precision BioSciences, Inc., Annual General Meeting, Jun 04, 2024

Precision BioSciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Precision BioSciences, Inc. has filed a Follow-on Equity Offering.

Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness

Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.

Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure

Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

Precision BioSciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Price target decreased by 15% to US$2.60

Precision BioSciences, Inc. Announces Management Changes

Consensus revenue estimates increase by 47%

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Price target decreased by 24% to US$5.07

Precision Biosciences, Inc. Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of in Vivo R&D Day

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Precision Biosciences, Inc. Announces Oral Presentation of Positive Arcus Gene Editing Data At International Liver Congress 2023

Precision Biosciences, Inc. Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at American Society of Gene & Cell Therapy 26th Annual Meeting

Consensus revenue estimates increase by 17%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 27%

Price target decreased by 11% to US$6.00

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, Its Lead Allogeneic Car T Clinical Candidate

Precision BioSciences, Inc. Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Less than half of directors are independent

Price target decreased to US$6.63

Precision BioSciences, Inc. Announces Raymond Schinazi Resigns from Board and as Chair of Nominating and Corporate Governance Committee and Member of Compensation Committee and Science and Technology Committee

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chief Financial Officer recently bought US$60k worth of stock

Precision BioSciences, Inc Announces Executive Promotions

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Precision BioSciences Q2 2022 Earnings Preview

Precision BioSciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Precision BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Precision BioSciences, Inc.(NasdaqGS:DTIL) dropped from Russell 2000 Dynamic Index

Chief Financial Officer recently bought US$51k worth of stock

Consensus forecasts updated

Price target decreased to US$10.63

Precision BioSciences, Inc. Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population

Precision Biosciences, Inc. Appoints Melinda Brown to its Board of Directors and Chair of the Board’s Audit Committee

Precision BioSciences, Inc. Appoints Juli Blanche as Chief People Officer

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precision Bio: Another CAR-T Laggard With No Solid Prospects

Precision BioSciences, Inc. to Report Q1, 2022 Results on May 09, 2022

Price target decreased to US$12.50

High number of new directors

Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Precision BioSciences, Inc. Announces Shalini Sharp Will Not Seek Re-Election to the Board of Directors

Precision BioSciences, Inc., Annual General Meeting, May 10, 2022

Precision BioSciences, Inc., Annual General Meeting, May 10, 2022

Chief Financial Officer recently bought US$51k worth of stock

Chief Financial Officer recently bought US$51k worth of stock

過去基準チェック /06